Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals has submitted copies of its unaudited financial results for the quarter and half year ended September 30, 2025, which were approved by the board on November 4, 2025 and published in Business Standard (English) and Prajasakti (Telugu) on November 5, 2025. Total operating income for Q2 FY26 fell sharply to Rs 417.41 lakhs from Rs 1,294.14 lakhs in Q2 FY25, a drop of roughly 68% year-on-year. The company posted a net loss of Rs 614.28 lakhs in Q2 FY26, slightly wider than the Rs 576.08 lakhs loss in the same quarter last year. For H1 FY26, the loss stood at Rs 1,146.71 lakhs versus Rs 1,093.20 lakhs in H1 FY25, with basic/diluted EPS of Rs (5.32) versus Rs (5.07) earlier.
This is a routine compliance filing (Regulation 30/47 newspaper publication), so it does not by itself move the stock, but the underlying numbers are concerning: a steep revenue decline combined with continued losses point to weakening operations and may weigh on investor sentiment.